Skip to content

The Effect of Valeriana 0fficinalis (Valerian) on Sleep Quality and Fatigue of Patients with Chronic Obstructive Pulmonary Disease

The Effect of Valeriana 0fficinalis (Valerian) Oral Extract on Sleep Quality and Fatigue of Patients with Chronic Obstructive Pulmonary Disease

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180413039292N1
Enrollment
60
Registered
2018-04-27
Start date
2018-04-29
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Chronic Obstructive Pulmonary Disease. Mucopurulent chronic bronchitis

Interventions

Intervention 1: Intervention group: Oral capsule of Valerian extract containing 300 mg of the root of the plant for four weeks, once a day (one hour before bedtime). Intervention 2: Control group: Ora

Sponsors

Islamic Azad University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease in stage one and two diseases, based on medical history and clinical symptoms and patient records Having some degree of fatigue, according to the Fatigue Severity Index (MFI), the total score obtained from fatigue in patients between 20 to 100 can be. The higher the score, the higher the fatigue Earn more than 6 points in response to Pittsburgh Sleep Quality Index Stable patient clinical condition (no acute problems) and no other chronic disease Aged 18 years and older Ability to read and write Persian texts Both sexes, both male and female Do not use other herbs during the intervention Not having a history of eczema and allergies to plants Complete vigilance Not having drug and alcohol addiction Not taking patients from benzodiazepines, sedative drugs, sleep deprivation and opiate during intervention Not Pregnant women of childbearing age

Exclusion criteria

Exclusion criteria: The occurrence of any physical and mental illness during the study that causes sleep disorder Existence of any significant changes in sleep conditions in an unpredictable way, including travel, change of location and ... Do not take capsules for up to 7 days during a month The patient's personal desire to quit for any reason Early diagnosis of obstructive apnea

Design outcomes

Primary

MeasureTime frame
Fatigue score in MFI fatigue questionnaire, sleep quality score in Pittsburgh questionnaire. Timepoint: Fatigue measurements were performed by the MFI fatigue and sleep quality questionnaire by Pittsburgh questionnaire before the intervention, after 2 weeks of the intervention and again at the end of week 4 after taking valerian. Method of measurement: MFI Fatigue Inventory, Pittsburgh Sleep Quality Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamaneh Shahabi

Islamic Azad University

samanehshahabi@ymail.com+98 21 6605 1482

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026